Anavex Life Sciences Q2 net loss narrows on lower R&D costs
AVXL•Outlook
- Anavex expects cash balance to fund operations into mid-to-late fiscal 2028.
- The company anticipates initiation of an ADME study for early Alzheimer's in Q3 2026.
- Anavex plans to engage the FDA on clinical strategy for early Alzheimer's and Fragile X.
Overview
- The US biopharma firm's preliminary fiscal Q2 net loss narrowed year over year.
- Lower research and development expenses drove a reduced operating loss after completion of a clinical trial.
- Preliminary results show cash balance expected to fund operations into mid-to-late fiscal 2028.
Key details
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q3 Loss Per Share | $0.06 | ||
| Q3 Net Loss | $5.30 mln |
- The one available analyst rating on the shares is "buy".
- The average consensus recommendation for the biotechnology & medical research peer group is "buy".
- Wall Street's median 12-month price target for Anavex Life Sciences Corp is $20.00, about 703.2% above its July 29 closing price of $2.49.
